The report filed Monday with the US District Court in Trenton, New Jersey, also recommends the creation of a new board committee to oversee the company’s health care and quality compliance issues.

The findings have been approved unanimously by Johnson & Johnson’s board.

The case was filed last year by shareholders against current and past members of its board of directors and management.

The plaintiffs claimed Johnson & Johnson breached its fiduciary duty as a result of a spate of kickback charges, product recalls and other problems.